**Supplementary table 1 – Baseline characteristics of the study groups in NSTE-ACS patients.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Ticagrelor** | **Prasugrel** | **p** |
| n | 511 | 223 |  |
| **Baseline characteristics** | | | |
| Age, years (median [IQR) | 60 [53, 66] | 58 [52, 66] | 0.096 |
| Gender (male) | 428 ( 83.9) | 187 ( 83.9) | 1.000 |
| Dyslipidemia | 361 ( 70.8) | 172 ( 77.1) | 0.092 |
| Hypertension | 305 ( 59.8) | 140 ( 62.8) | 0.498 |
| Current smokers | 215 ( 42.2) | 127 ( 57.0) | <0.001 |
| Diabetes mellitus | 194 ( 38.1) | 95 ( 42.8) | 0.268 |
| Family history of CAD | 189 ( 43.3) | 86 ( 48.3) | 0.301 |
| Prior MI | 170 ( 33.3) | 81 ( 36.7) | 0.434 |
| Prior CABG | 29 ( 5.7) | 17 ( 7.6) | 0.411 |
| Prior PCI | 158 ( 31.1) | 76 ( 34.2) | 0.455 |
| Chronic renal failure | 29 ( 5.7) | 11 ( 5.0) | 0.823 |
| PVD | 19 ( 3.7) | 11 ( 4.9) | 0.578 |
| History of CHF | 22 ( 4.3) | 15 ( 6.8) | 0.229 |
| Grace score>140 | 10 ( 2.2) | 7 ( 3.5) | 0.483 |
| **Prior medications** | | | |
| Aspirin | 210 ( 44.5) | 105 ( 50.2) | 0.192 |
| Clopidogrel | 38 ( 8.4) | 15 ( 7.6) | 0.847 |
| ACE-I / ARB | 199 (39.0) | 100 (44.8) | 0.163 |
| Beta blockers | 158 ( 35.6) | 77 ( 40.3) | 0.297 |
| Statins | 232 ( 58.9) | 107 ( 59.8) | 0.912 |
| Hypoglycemic agents | 139 ( 27.3) | 64 ( 28.7) | 0.766 |
| Diuretics | 39 ( 10.0) | 21 ( 11.6) | 0.664 |
| Abbreviations: NSTE-ACS – Non ST elevation acute coronary syndrome; STEMI – ST elevation myocardial infarction; PSM – propensity score matched; CAD – coronary artery disease; MI – myocardial infarction; CABG – coronary artery bypass grafting; PCI – percutaneous coronary intervention; PVD – peripheral vascular disease; CHF – congestive heart failure; | | | |

**Supplementary table 2 – Drug treatment in in NSTE-ACS patients, at discharge and at 30-day follow up.**

|  | **Ticagrelor** | **Prasugrel** | **p** |
| --- | --- | --- | --- |
| n | 511 | 223 |  |
| **Treatment at discharge** | | | |
| Aspirin | 507 ( 99.4) | 219 ( 98.6) | 0.544 |
| P2Y12 | 503 ( 98.6) | 220 ( 98.7) | 1.000 |
| Statins | 498 ( 98.6) | 219 ( 98.6) | 1.000 |
| ACE-I/ARB | 401 ( 85.7) | 188 ( 86.6) | 0.829 |
| Beta blockers | 393 ( 82.6) | 166 ( 78.7) | 0.271 |
| **Treatment at 30-day follow-up** | | | |
| Cardiac rehabilitation (referral) | 285 ( 65.2) | 105 ( 56.8) | 0.057 |
| Aspirin | 413 ( 97.9) | 180 ( 97.8) | 1.000 |
| Clopidogrel | 29 (6.8) | 11 (5.9) | 0.833 |
| Prasugrel | 6 ( 1.4) | 160 (87) | <0.001 |
| Ticagrelor | 380 (89.2) | 7 (3.8) | <0.001 |
| Statins | 408 ( 98.6) | 178 ( 97.8) | 0.757 |
| ACE-I / ARB | 325 (84.9) | 155 (87.6) | 0.469 |
| Beta Blockers | 325 ( 82.3) | 136 ( 79.1) | 0.433 |
| Abbreviations: STEMI – ST elevation myocardial infarction; PSM – propensity score matched. | | | |